The Lancet 柳叶刀· Shaodong Hong, Ting Zhou, Xue Hou, Xiangjiao Meng, Zhihuang Hu, Wei Zheng, Jiuwei Cui, Yongzhong Luo, Lin Wu, Meijuan Huang, Haipeng Xu, Jie Hu, Yanqiu Zhao, Wenxiu Yao, Yonggui Hong, Jun Cai, Yu Zhang, Chunxia Su, Conghua Xie, Ruoyu Wang, Xiang Li, Qiong He, Liang Zhang, Ruiling Ning, Daren Lin, Tongmei Zhang, Tienan Yi, Liqiang Zhong, Siyuan Huang, Hui Zhao, Jian Fang, Qing Bu, Bihui Li, Zhiye Zhang, Meiqi Shi, Jianhua Shi, Zhiping Deng, Yi Zhu, Hai Zhu, Sa Xiao, Lei Yang, Ni Song, Wenfeng Fang, Li Zhang, Yunpeng Yang, PANKU-Lung01 Investigators·· 25 天前精选AI 评分73
Izalontamab brengitecan vs 含铂化疗治疗三代EGFR-TKI进展后EGFR突变晚期非鳞NSCLC的III期结果
[Articles] Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China
AI 导读
中国多中心、随机、开放标签III期PANKU-Lung01试验报告,三代EGFR-TKI进展后EGFR突变晚期非鳞状非小细胞肺癌患者接受Izalontamab brengitecan较含铂化疗显著延长无进展生存期,但≥3级治疗相关不良事件发生率更高;该结果被认为是首个双特异性抗体偶联药物的III期证据。
推荐理由
原文给出了III期RCT的主要终点结果与安全性比较,读者可了解该双抗ADC药物在此类患者中的获益风险位置。
来源:The Lancet 柳叶刀 · thelancet.com